In an older adult with a recent cerebrovascular accident and visual field loss, does quetiapine effectively treat post‑stroke visual hallucinations?

Quetiapine for Post-Stroke Visual Hallucinations

Quetiapine is not recommended for treating post-stroke visual hallucinations in older adults, as there is no evidence supporting its efficacy for this indication and substantial evidence of serious cardiovascular and other risks in this population.

Clinical Context and Mechanism

Post-stroke visual hallucinations in older adults with visual field loss represent a distinct clinical entity that requires careful diagnostic consideration:

Differential Diagnosis

• Charles Bonnet Syndrome (CBS): Visual hallucinations due to cortical release phenomena from reduced visual input, characterized by insight that images are not real and absence of other neurological explanations 1
• Post-stroke epilepsy: Complex visual hallucinations may reflect epileptic activity spreading to temporal or parietal regions 2
• Other causes: Delirium, dementia, medication effects, or psychiatric disorders 1

Critical distinction: Post-stroke visual hallucinations with visual field loss likely represent CBS-like phenomena rather than a primary psychiatric condition requiring antipsychotic treatment.

Evidence Against Quetiapine Use

Lack of Efficacy Evidence

The 2023 Vision Rehabilitation Guidelines explicitly state: "Although a range of pharmacological treatments is reported in case reports, there is currently no significant evidence of efficacy" for treating visual hallucinations associated with vision loss 1. This applies directly to post-stroke visual hallucinations with visual field deficits.

Substantial Safety Concerns in Older Adults

Cardiovascular risks are particularly concerning:

• Low-dose quetiapine increases risk of major adverse cardiovascular events (aHR=1.52), non-fatal ischemic stroke (aHR=1.37), and cardiovascular death (aHR=1.90) 3
• Risk is greater in women and those ≥65 years 3
• In stroke patients specifically, quetiapine causes orthostatic hypotension, syncope, and falls 4

Additional risks in older adults 4, 5:

• Somnolence (25-39%), dizziness (15-27%), postural hypotension (6-18%)
• Increased mortality in patients with parkinsonism and dementia
• Cognitive impairment and increased fall risk
• QT prolongation, particularly concerning in cardiovascular disease 4
• Tardive dyskinesia with chronic use 4

The 2019 AGS Beers Criteria and 2015 AGS Postoperative Delirium Guidelines recommend avoiding antipsychotics for non-agitated hallucinations 6, 7.

Recommended Management Approach

First-Line: Non-Pharmacological Management

Education and reassurance are therapeutic 1:

1. Explain the cortical release mechanism to patient and family
2. Reassure that hallucinations are common with vision loss and do not indicate psychiatric illness
3. This discussion alone provides "significant relief and decreased anxiety" 1

Self-Management Techniques

Recommend patients try 1:

• Eye movements
• Changing lighting conditions
• Distraction techniques

Rule Out Alternative Diagnoses

Atypical features requiring neuropsychiatric evaluation 1:

• Lack of insight that images are unreal despite explanation
• Interactive hallucinations
• Associated neurological signs or symptoms
• Consider post-stroke epilepsy if hallucinations involve episodic memory scenes 2

When Pharmacological Treatment Might Be Considered

Only if hallucinations cause severe distress or agitation threatening substantial harm, and only after non-pharmacological approaches fail 7:

• Use lowest effective dose for shortest duration
• Recognize this is off-label with no efficacy evidence
• Carefully weigh cardiovascular risks, especially in women and elderly
• Monitor blood pressure, falls, cognitive function, and cardiovascular status closely

Rehabilitation Focus

The 2016 AHA/ASA Stroke Rehabilitation Guidelines emphasize compensatory scanning training for visual field deficits rather than pharmacological treatment of hallucinations 8.

Common Pitfalls to Avoid

1. Misdiagnosing CBS as primary psychosis requiring antipsychotic treatment
2. Overlooking post-stroke epilepsy as the cause of complex visual hallucinations 2
3. Underestimating cardiovascular risks of quetiapine in recent stroke patients
4. Skipping education and reassurance, which are often sufficient treatment
5. Using quetiapine prophylactically without clear indication

Clinical Algorithm

Post-stroke visual hallucinations + visual field loss
↓
1. Assess for CBS criteria (insight, no other neurological cause)
2. Rule out post-stroke epilepsy (consider EEG if atypical features)
3. Educate patient/family about cortical release mechanism
4. Teach self-management techniques
↓
If distress persists:
5. Psychological support/therapy (moderate evidence for benefit) [1]
6. Consider non-pharmacological interventions only
↓
Avoid quetiapine unless:
- Severe agitation threatening harm AND
- All other approaches failed AND
- Cardiovascular risk carefully assessed

In summary: Education and reassurance should be the primary intervention, as pharmacological treatments including quetiapine lack efficacy evidence and carry substantial risks in this vulnerable population.